Full-Time

Software Engineer

Full Stack, Notebook Canvas

Confirmed live in the last 24 hours

Benchling

Benchling

501-1,000 employees

Cloud-based platform for life sciences R&D

Compensation Overview

$141.1k - $190.9k/yr

Mid

San Francisco, CA, USA

Hybrid

Employees are expected to be on-site 3 days per week.

Category
Full-Stack Engineering
Software Engineering
Required Skills
JavaScript
React.js
Product Management
Requirements
  • 3+ years of experience in a fulltime software engineering role
  • Experience developing both user-facing & backend experiences in a web application
  • Experience with React, or similar javascript-based frontend application frameworks
  • Experience leading & delivering projects from start to finish, independently or as a part of a larger team
  • Build software with a product-first approach
  • Enjoy a high-degree of ownership in key areas of the software product you’re building
  • Are interested in learning more about life science (prior knowledge is not required; desire to learn is a must)
Responsibilities
  • Build large-scale projects end-to-end, from ideation with cross-functional partners, through to rollout to end-users
  • Engineer across our stack, from designing and implementing backend models & APIs to crafting rich frontend components and architecture
  • Collaborate closely with product managers, designers, and other teams to build the best product possible for our users
  • Create entirely net-new products, while also investing in taking existing products to feature completeness
  • Be a core team member, helping to shape the way we work together, while also participating in technical & architectural discussions among engineers inside & outside the team
Desired Qualifications
  • Desire to learn more about life science (prior knowledge is not required)

Benchling offers a platform for life sciences research and development, catering to biotech and pharmaceutical companies, academic institutions, and research organizations. Its cloud-based tools, including an electronic lab notebook and molecular biology tools, help scientists manage data, collaborate, and streamline workflows. The company operates on a subscription model with various pricing tiers and provides tailored enterprise solutions. Benchling's goal is to enhance the efficiency of scientific research, enabling clients to accelerate their innovations.

Company Size

501-1,000

Company Stage

Series F

Total Funding

$412M

Headquarters

San Francisco, California

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for cloud-based R&D solutions boosts Benchling's market potential.
  • AI-driven research collaborations, like with Moderna, enhance Benchling's technological edge.
  • Benchling's expansion to over 1,000 companies indicates strong market acceptance.

What critics are saying

  • Emerging competitors offering similar solutions at lower costs threaten Benchling's market share.
  • Rapid AI advancements may require Benchling to invest heavily to stay competitive.
  • Data privacy concerns could lead to regulatory challenges for Benchling's platform.

What makes Benchling unique

  • Benchling offers a comprehensive cloud-based platform tailored for life sciences R&D.
  • The platform integrates AI and machine learning for advanced data management and analysis.
  • Benchling's partnerships with top biopharma companies enhance its credibility and market reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Four months of fully paid parental leave

401(k) plan

Remote working stipend

Yearly company-wide retreat

Monthly gym and wellness stipend

Commuter benefits

100% premiums covered for health, dental, and vision

Weekly company social events

Flexible PTO and company-wide winter holiday shutdown

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Jun 11th, 2025
Benchling Announces Collaboration With Merck On Vaccine Bioanalysis

Unified platform drives bioanalytical capacity, throughput, and efficiency in regulated environment SAN FRANCISCO, June 11, 2025 /PRNewswire/ -- Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a software framework that helps bring Merck's pre-clinical and clinical bioanalytical workflows onto one flexible, fully integrated platform. The collaboration focuses on three key areas: enhancing speed and throughput with automated data capture and integration; streamlining with a unified platform for managing workflows and data across the bioanalytical lifecycle; and maintaining rigorous quality and compliance standards in a regulated bioanalytical setting. "Our work with Merck demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis," said Sajith Wickramasekara, co-founder and CEO of Benchling. "By focusing on the modern demands of bioanalytical labs, we're delivering an approach that aims to enhance efficiency throughout the vaccine development lifecycle." "Sophisticated data management capabilities are integral to advancing vaccine research and development," said Roy Helmy, Associate Vice President, Regulated Bioanalytics at Merck Research Laboratories. "We're thrilled to collaborate with the team at Benchling on a digital integration that enables our scientists to access, analyze, and harness data insights throughout the development process." About Benchling Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling RD Cloud as their central source of truth for scientific data, analysis, and collaboration

Things of Business
May 7th, 2025
Benchling and Moderna Collaborate on AI-Driven Research

SAN FRANCISCO and BOSTON, May 7, 2025 - Benchling, the R&D platform powering the biotech industry, today announced an expanded collaboration with Moderna.

Benchling
Oct 23rd, 2024
Benchling acquires PipeBio to accelerate AI-powered antibody discovery

We’re excited to announce Benchling’s acquisition of PipeBio, a leader in high-throughput bioinformatics analysis, to drive biologics discovery.

ArcticStartup
Oct 22nd, 2024
Danish startup joins US-based Benchling, aiming to revolutionize antibody discovery

The collaboration is expected to improve the efficiency of the discovery process by combining PipeBio's advanced sequence analysis tools with Benchling's established software ecosystem.

SynBioBeta
Oct 10th, 2024
Novonesis Teams Up with Benchling to Supercharge Biosolutions R&D

In a significant move to streamline its R&D operations, Novonesis, a global leader in biosolutions, has selected Benchling as its digital platform to enhance the discovery, development, and testing processes across its scientific teams.